Quentis debuts with $48M series A

Quentis Therapeutics Inc. (New York, N.Y.) raised $48 million in a series A round led by existing investor Versant Ventures and new investor Polaris Partners. New investors AbbVie Ventures, Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan), Yonghua Capital, Alexandria Venture Investments and New York Ventures -- the venture arm of Empire State Development -- also participated.

Quentis is developing small molecules that inhibit the endoplasmic reticulum (ER) stress response pathway, which promotes tumor cell growth and impedes the anti-tumor immune response (see BioCentury, Feb. 27)...